| Literature DB >> 31366407 |
Lara A Aqrawi1, Hilde Kanli Galtung2, Eduarda M Guerreiro3, Reidun Øvstebø4, Bernd Thiede5, Tor Paaske Utheim3,4,6, Xiangjun Chen1,7, Øygunn Aass Utheim4,7, Øyvind Palm8, Kathrine Skarstein9,10, Janicke Liaaen Jensen1.
Abstract
BACKGROUND: Mononuclear cell infiltration of exocrine glands, production of Ro/SSA and La/SSB autoantibodies, along with oral and ocular dryness, are characteristic features of primary Sjögren's syndrome (pSS). Non-SS sicca subjects, an underexplored group in relation to pSS, display similar sicca symptoms, with possible mild signs of inflammation in their salivary glands, yet with no serological detection of autoantibody production. In this study, we investigated inflammatory manifestations in the salivary gland tissue, tear fluid and saliva of non-SS subjects, as compared to pSS patients and healthy individuals.Entities:
Keywords: Adaptive immunity; Autoimmunity; Biomarkers; Extracellular vesicles; Innate immunity; Proteomics; Saliva; Sicca subjects; Sjögren’s syndrome; Tears
Mesh:
Substances:
Year: 2019 PMID: 31366407 PMCID: PMC6670195 DOI: 10.1186/s13075-019-1961-4
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Clinical characteristics of non-SS subjects included in the proteomics analysis
| Patient no. | Age | Gender | Anti-SSA* | Anti-SSB* | Focus score** | FI score*** | Schirmer test**** | Saliva secretion ***** | Dry mouth | Dry eyes |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 71 | F | – | – | < 1 | 1 | + | + | + | + |
| 2 | 33 | F | – | – | 0 | 1 | + | NT | + | + |
| 3 | 48 | F | – | – | 0 | 0 | + | + | + | + |
| 4 | 65 | F | – | – | 0 | 2 | + | + | + | + |
| 5 | 39 | F | – | – | 0 | 0 | + | + | + | + |
| 6 | 44 | F | – | – | 0 | 0 | – | + | + | + |
| 7 | 30 | F | – | – | 0 | 0 | – | + | + | + |
| 8 | 56 | F | – | – | 0 | 1 | + | + | + | + |
| 9 | 41 | F | – | – | 0 | 0 | + | + | + | + |
| 10 | 50 | F | – | – | 0 | 0 | + | + | + | + |
| 11 | 47 | F | – | – | 0 | 1 | + | – | + | + |
| 12 | 64 | F | – | – | < 1 | 0 | + | + | + | + |
| 13 | 73 | F | – | – | 0 | 2 | + | + | + | + |
| 14 | 59 | F | – | – | < 1 | 0 | + | + | + | + |
| 15 | 51 | F | – | – | < 1 | – | + | + | + | + |
F female, FI fatty infiltration, NT not tested
*Autoantibody production was assessed by ELISA
**Values are the number of focal infiltrates/4mm2 tissue area containing > 50 mononuclear cells
***The degree of fatty infiltration was assessed and the sections were scored blindly, where no or little fatty infiltration = 0, moderate = 1, and prominent = 2
****Values are in mm/5 min; normal flow > 5 mm/5 min. ‘+’ indicates dryness and tear secretion ≤ 5 mm/5 min
*****Values are in ml/15 min; normal flow > 1.5 ml/15 min. ‘+’ indicates dryness and unstimulated whole saliva secretion ≤ 1.5 ml/15 min
Clinical characteristics of pSS patients included in the study
| Patient no. | Age | Gender | Anti-SSA* | Anti-SSB* | Focus score** | GC | FI score*** | Schirmer test**** | Saliva secretion ***** | Dry mouth | Dry eyes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 48 | F | + | + | – | – | – | + | + | + | + |
| 2 | 59 | F | + | + | – | – | – | + | + | + | + |
| 3 | 52 | F | + | + | 8 | + | 1 | + | + | + | + |
| 4 | 54 | F | + | – | 1 | – | 2 | + | + | – | + |
| 5 | 60 | F | + | + | 3 | + | 1 | + | + | – | – |
| 6 | 64 | F | + | – | 0 | – | 1 | + | + | + | + |
| 7 | 55 | F | + | – | 0 | – | 2 | + | + | + | + |
| 8 | 50 | F | + | + | – | – | – | + | – | + | + |
| 9 | 35 | F | + | + | 3 | + | 0 | + | + | – | – |
| 10 | 75 | F | + | + | – | – | – | + | – | + | + |
F female, GC germinal centres, FI fatty infiltration
*Autoantibody production was assessed by ELISA
**Values are the number of focal infiltrates/4mm2 tissue area containing > 50 mononuclear cells
***The degree of fatty infiltration was assessed and the sections were scored blindly, where no or little fatty infiltration = 0, moderate = 1, and prominent = 2
****Values are in mm/5 min; normal flow > 5 mm/5 min. ‘+’ indicates dryness and tear secretion ≤ 5 mm/5 min
*****Values are in ml/15 min; normal flow > 1.5 ml/15 min. ‘+’ indicates dryness and unstimulated whole saliva secretion ≤ 1.5 ml/15 min
Characterisation of EVs in saliva and tears
| Mean particle size* | Particles/mL* | CD9 + EVs** | |
|---|---|---|---|
| Tear fluid | |||
| Pool of patients with pSS ( | 255 ± 40 | 5.0 E+08 | 1.04 |
| Pool of patients with non-SS ( | 204 ± 8 | 1.2 E+09 | 1.22 |
| Pool of controls ( | 215 ± 9 | 7.1 E+08 | 1.20 |
| Saliva | |||
| Patients with pSS ( | 233 ± 17 | 1.9 E+10 ± 0.7E+9 | 4.32 ± 1.19 |
| Patients with non-SS ( | 231 ± 13 | 1.0 E+10 ± 1.6E+9 | 3.98 ± 0.57 |
| Controls ( | 264 ± 6 | 7.9 E+9 ± 1.6E+9 | 3.22 ± 0.98 |
*Nanoparticle tracking analysis was conducted on EV joint fractions from pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls) and whole saliva (n = 9 pSS, n = 14 non-SS and n = 10 controls), to determine mean particle size of microvesicles and exosomes (nm ± SEM), in addition to concentrations of EVs (particles/ml ± SEM)
**Detection of CD9+ EVs from joint fractions of pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls), and whole saliva (n = 9 pSS, n = 14 non-SS and n = 10 controls) was performed by immunoaffinity capture using anti-CD9 coated magnetic beads followed by flow cytometry analysis. The results were reported as signal to noise (S/N) ratios of median fluorescence intensity (MFI)
Fig. 1Histopathological evaluation of minor salivary gland biopsies shows implications of inflammation in the target organ of non-SS sicca subjects. Haematoxylin and eosin staining of minor salivary gland biopsies taken from the non-SS and pSS subjects included in the study allowed the evaluation for mononuclear cell infiltration, fibrosis, and the presence of fatty infiltration in their salivary gland tissue. a Non-SS subject with normal salivary gland morphology. b Non-SS individual with fibrosis in the salivary gland tissue. c Non-SS participant with mild focal inflammation in the salivary gland and a focus score < 1. d Salivary gland biopsy of a pSS patient with a focus score value of 3 and GC-like structure within the focal infiltrate. Areas of inflammation are indicated by black arrow
Fig. 2Upregulation of proinflammatory pathways detected in tear fluid of pSS patients. For functional analysis of the proteomics data, DAVID (v 6.7, https://david.ncifcrf.gov) was applied using a FDR with a maximum 5% cut-off, and cellular processes for the upregulated proteins in the pSS patients were identified. FunRich (http://www.funrich.org/) was then used to visualise the fraction of proteins involved in each of these upregulated signalling pathways. a Upregulated signalling pathways identified in the pSS patients, as compared to non-SS sicca controls. b Comparing pSS patients to healthy controls helped detect similar cellular processes as with the non-SS subjects, affecting both innate and adaptive immunological processes. Percentage values indicate the amount of overexpressed proteins involved in upregulating each of the cellular processes identified
Highly upregulated proteins in tear fluid of pSS patients
| Number | Gene | Related protein* | Classification and function** |
|---|---|---|---|
| Non-SS vs. pSS | |||
| 1 | LMO7 | LIM domain only protein 7 | Ubiquitination, cell signalling, cell adhesion |
| 2 | HUWE1 | E3 ubiquitin-protein ligase HUWE1 | Mediates ubiquitination, neutrophil degranulation, cell differentiation |
| 3 | TPD52 | Tumour protein D52 | B cell differentiation, cell proliferation, Ca2+-signalling |
| Controls vs. pSS | |||
| 1 | LMO7 | LIM domain only protein 7 | Ubiquitination, cell signalling, cell adhesion |
| 2 | HUWE1 | E3 ubiquitin-protein ligase HUWE1 | Mediates ubiquitination, neutrophil degranulation, cell differentiation |
| 3 | TPD52 | Tumour protein D52 | B cell differentiation, cell proliferation, Ca2+-signalling |
*The three most upregulated immunological proteins in whole saliva of pSS patients deviating in replicates, i.e. number of individuals (frequency), and spectral counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://www.proteomesoftware.com/products/scaffold/)
**The classification and functions of the proteins presented were identified using publicly available databases, such as UniProt (http://www.uniprot.org)
Fig. 3Overexpression of proteins regulating cellular innate and adaptive immunological pathways detected in EVs from tear fluid of pSS patients. Following LC-MS of EVs extracted from tear fluid, DAVID analysis (v 6.7, https://david.ncifcrf.gov) was applied using a FDR with a maximum cut-off of 5%. Cellular processes for the upregulated proteins in the pSS patients were identified, and FunRich (http://www.funrich.org/) was then used to visualise the segment of proteins involved. a Upregulated signalling pathways distinguished in EVs isolated from tears of pSS patients, as compared to non-SS subjects. b Comparing pSS patients to healthy controls, the most upregulated of cellular processes in the pSS patient group was again retina homeostasis, followed by other central innate and adaptive immune responses. Percentage values represent the fraction of overexpressed proteins contributing to the upregulation of each cellular process
Highly upregulated proteins in stimulated whole saliva of pSS patients
| Number | Gene | Related protein* | Classification and function** |
|---|---|---|---|
| Non-SS vs. pSS | |||
| 1 | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | T cell activation and proliferation, upregulation of NF-kappa-B signalling |
| 2 | CD44 | CD44 antigen | FOXP3 expression and regulatory T cell suppression, promotes tumour growth |
| 3 | B2MG | Beta-2-microglobulin | Antigen processing and presentation on MHC class I, innate immunity |
| Controls vs. pSS | |||
| 1 | SLUR1 | Secreted Ly-6/uPAR-related protein 1 | Acetylcholine receptor activity, cell migration and proliferation |
| 2 | B2MG | Beta-2-microglobulin | Antigen processing and presentation on MHC class I, innate immunity |
| 3 | CLUS | Clusterin | Innate immunity, modulates NF-kappa-B activity and TNF production |
*The three most upregulated immunological proteins in whole saliva of pSS patients deviating in replicates, i.e. number of individuals (frequency), and spectral counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://www.proteomesoftware.com/products/scaffold/)
**The classification and functions of the proteins presented were identified using publicly available databases, such as UniProt (http://www.uniprot.org)
Highly upregulated proteins in EVs isolated from stimulated whole saliva of pSS patients
| Number | Gene | Related protein* | Classification and function** |
|---|---|---|---|
| Non-SS vs. pSS | |||
| 1 | CD44 | CD44 antigen | FOXP3 expression and regulatory T-cell suppression, promotes tumour growth |
| 2 | MVP | Major vault protein | IFNγ-mediated signalling, MAP kinase activity, neutrophil degranulation |
| 3 | NGAL | Neutrophil gelatinase-associated lipocalin | Innate immunity, tumour-associated antigen, cell adhesion |
| Controls vs. pSS | |||
| 1 | FCN1 | Ficolin-1 | Pattern-recognition receptor in innate immunity, complement activation |
| 2 | CD44 | CD44 antigen | FOXP3 expression and regulatory T-cell suppression, promotes tumour growth |
| 3 | ANXA4 | Annexin A4 | NF-kappaB binding, apoptosis, IL-8 secretion |
*The three most upregulated immunological proteins in whole saliva of pSS patients deviating in replicates i.e. number of individuals (frequency), and spectral counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://www.proteomesoftware.com/products/scaffold/)
**The classification and functions of the proteins presented were identified using publicly available databases, such as UniProt (http://www.uniprot.org)